DepoAmikacin: DEPO completed a Phase I study showing DepoAmikacin to be well-tolerated.

DEPO is assessing in animal studies a number of potential indications for Phase II trials, including peritonitis, infected vascular grafts, infected joints and prophylaxis of wounds. Depending on how ...